Clinical investigation of ciprofloxacin IV in severe and/or refractory infections in the internal medicine field

Kohei Hara; Shigeru Kohno; Jun Ichi Kadota; Kazunori Tomono; Yoichi Hirakata; Shigefumi Maesaki; Masao Nakatomi; Sadahiro Asai; Kazuhiro Okuno; Naomi Itoh; Yuichi Inoue; Yuko Yamashita; Takao Koike; Katsunori Onishi; Mitsuhide Omichi; Yomei Hiraga; Akira Watanabe; Toshihiro Nukiwa; Kazuo Sato; Toshio Nakamura; Masaaki Arakawa; Kouichi Wada; Kenichi Igarashi; Yoshinori Shimazu; Yukiyoshi Kon; Hiroyuki Sega; Osamu Sekine; Yasutoshi Suzuki; Nobuki Aoki; Takao Takizawa; Toshinori Kanemura; Hisashi Takemura; Kohshu Nagao; Yoshio Hamashima; Yoshio Sakamoto; Kenji Sakata; Takeo Toyoda; Mitsuhiko Ohsumi; Yukio Noguchi; Hiroyuki Kobayashi; Shin Kawai; Hiroshi Sugiura; Susumu Sakayori; Hiroshi Oshitani; Takashi Inamatsu; Yoshishige Masuda; Yasuyuki Sano; Yasuo Arai; Chuhei Ogawa; Hirokazu Yamada; Kohya Shiba; Masaki Yoshida; Kazuhisa Okada; Tetsuo Sato; Futoshi Kotajima; Izumi Hayashi; Harumi Shishido; Atsuyuki Kurashima; Fumio Matsumoto; Iwao Sakurai; Jingoro Shimada; Shigeki Odagiri; Kaneo Suzuki; Yuji Watanuki; Kenichi Takahashi; Toshiyuki Yamamoto; Kaoru Shimokata; Hidehiko Saito; Shuzo Sakai; Keisuke Nishiwaki; Masashi Yamamoto; Masamitsu Iwata; Hiroshi Saito; Fumio Miki; Nobuhiro Narita; Keiichi Mikasa; Yoshihito Niki; Toshiharu Matsushima; Rinzo Soejima; Yoshiro Sawae; Koji Takaki; Kotaro Oizumi; Shouji Kinoshita; Yoshiyuki Mitsutake; Fumio Tanaka; Masashi Kawahara; Tsuyoshi Nagatake; Yoshiaki Utsunomiya; Moritoshi Akiyama; Masaru Nasu; Atsuro Hashimoto; Shigeru Matsukura; Hideo Mashimoto; Kazuhito Hiratani; Atsushi Saito; Masao Tateyama; Takashi Shinzato; Hiroyuki Uechi; Futoshi Higa

Clinical investigation of ciprofloxacin IV in severe and/or refractory infections in the internal medicine field

Kohei Hara, Shigeru Kohno, Jun Ichi Kadota, Kazunori Tomono, Yoichi Hirakata, Shigefumi Maesaki, Masao Nakatomi, Sadahiro Asai, Kazuhiro Okuno, Naomi Itoh, Yuichi Inoue, Yuko Yamashita, Takao Koike, Katsunori Onishi, Mitsuhide Omichi, Yomei Hiraga, Akira Watanabe, Toshihiro Nukiwa, Kazuo Sato, Toshio NakamuraMasaaki Arakawa, Kouichi Wada, Kenichi Igarashi, Yoshinori Shimazu, Yukiyoshi Kon, Hiroyuki Sega, Osamu Sekine, Yasutoshi Suzuki, Nobuki Aoki, Takao Takizawa, Toshinori Kanemura, Hisashi Takemura, Kohshu Nagao, Yoshio Hamashima, Yoshio Sakamoto, Kenji Sakata, Takeo Toyoda, Mitsuhiko Ohsumi, Yukio Noguchi, Hiroyuki Kobayashi, Shin Kawai, Hiroshi Sugiura, Susumu Sakayori, Hiroshi Oshitani, Takashi Inamatsu, Yoshishige Masuda, Yasuyuki Sano, Yasuo Arai, Chuhei Ogawa, Hirokazu Yamada, Kohya Shiba, Masaki Yoshida, Kazuhisa Okada, Tetsuo Sato, Futoshi Kotajima, Izumi Hayashi, Harumi Shishido, Atsuyuki Kurashima, Fumio Matsumoto, Iwao Sakurai, Jingoro Shimada, Shigeki Odagiri, Kaneo Suzuki, Yuji Watanuki, Kenichi Takahashi, Toshiyuki Yamamoto, Kaoru Shimokata, Hidehiko Saito, Shuzo Sakai, Keisuke Nishiwaki, Masashi Yamamoto, Masamitsu Iwata, Hiroshi Saito, Fumio Miki, Nobuhiro Narita, Keiichi Mikasa, Yoshihito Niki, Toshiharu Matsushima, Rinzo Soejima, Yoshiro Sawae, Koji Takaki, Kotaro Oizumi, Shouji Kinoshita, Yoshiyuki Mitsutake, Fumio Tanaka, Masashi Kawahara, Tsuyoshi Nagatake, Yoshiaki Utsunomiya, Moritoshi Akiyama, Masaru Nasu, Atsuro Hashimoto, Shigeru Matsukura, Hideo Mashimoto, Kazuhito Hiratani, Atsushi Saito, Masao Tateyama, Takashi Shinzato, Hiroyuki Uechi, Futoshi Higa

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

The efficacy, safety and usefulness of injectable ciprofloxacin (CPFX) were investigated in a clinical study involving treatment of patients with severe and/or refractory infections in the internal medicine field. The test drug was administered by intravenous drip infusion at a dose of 300 mg (as CPFX), twice daily for 3 to 14 days. A total of 66 cases were enrolled in this study: 16 cases with chronic bronchitis, 23 with infectious bronchiectasis, 20 with secondary infection with chronic respiratory disease and 2 with empyema, but 5 cases had ineligible diseases. The clinical efficacy rate was 69.1% (38/55 cases), being 92.3% (12/13) for chronic bronchitis, 59.1% (13/22) for infectious bronchiectasis, 72.2% (13/18) for secondary infection with chronic respiratory disease. The subtotals were 71.7% (38/53) for the above chronic lower RTIs and 0/2 for empyema. The efficacy rate in poor responders to antibiotic pretreatment was 66.7% (8/12 cases). The elimination rate of causative organisms was 65.7% (23/35 strains), in terms of bacteriological efficacy. Side effects were noted in 11.3% (7/62) with 10 events. The major signs and symptoms were central nervous system disorders and gastro-intestinal symptoms, all of which were mild to moderate, and disappeared during treatment or after the completion of treatment or drug discontinuation. Abnormal laboratory findings were seen in 13.1% (8/61) with 19 events, mostly GOT, GPT and/or γ -GTP elevation. In the evaluation of overall safety, a safety rate of 77.4% (48/62 cases) was obtained, yielding a 62.1% (36/58 cases) usefulness rate. Therefore, the present study confirmed good effectiveness and safety for injectable CPFX in the treatment of severe and/or refractory chronic airway infections.

Original language	English
Pages (from-to)	933-935
Number of pages	3
Journal	Japanese Journal of Chemotherapy
Volume	45
Issue number	11
Publication status	Published - 1997
Externally published	Yes

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Hara, K., Kohno, S., Kadota, J. I., Tomono, K., Hirakata, Y., Maesaki, S., Nakatomi, M., Asai, S., Okuno, K., Itoh, N., Inoue, Y., Yamashita, Y., Koike, T., Onishi, K., Omichi, M., Hiraga, Y., Watanabe, A., Nukiwa, T., Sato, K., ... Higa, F. (1997). Clinical investigation of ciprofloxacin IV in severe and/or refractory infections in the internal medicine field. Japanese Journal of Chemotherapy, 45(11), 933-935.

Hara, K, Kohno, S, Kadota, JI, Tomono, K, Hirakata, Y, Maesaki, S, Nakatomi, M, Asai, S, Okuno, K, Itoh, N, Inoue, Y, Yamashita, Y, Koike, T, Onishi, K, Omichi, M, Hiraga, Y, Watanabe, A, Nukiwa, T, Sato, K, Nakamura, T, Arakawa, M, Wada, K, Igarashi, K, Shimazu, Y, Kon, Y, Sega, H, Sekine, O, Suzuki, Y, Aoki, N, Takizawa, T, Kanemura, T, Takemura, H, Nagao, K, Hamashima, Y, Sakamoto, Y, Sakata, K, Toyoda, T, Ohsumi, M, Noguchi, Y, Kobayashi, H, Kawai, S, Sugiura, H, Sakayori, S, Oshitani, H, Inamatsu, T, Masuda, Y, Sano, Y, Arai, Y, Ogawa, C, Yamada, H, Shiba, K, Yoshida, M, Okada, K, Sato, T, Kotajima, F, Hayashi, I, Shishido, H, Kurashima, A, Matsumoto, F, Sakurai, I, Shimada, J, Odagiri, S, Suzuki, K, Watanuki, Y, Takahashi, K, Yamamoto, T, Shimokata, K, Saito, H, Sakai, S, Nishiwaki, K, Yamamoto, M, Iwata, M, Saito, H, Miki, F, Narita, N, Mikasa, K, Niki, Y, Matsushima, T, Soejima, R, Sawae, Y, Takaki, K, Oizumi, K, Kinoshita, S, Mitsutake, Y, Tanaka, F, Kawahara, M, Nagatake, T, Utsunomiya, Y, Akiyama, M, Nasu, M, Hashimoto, A, Matsukura, S, Mashimoto, H, Hiratani, K, Saito, A, Tateyama, M, Shinzato, T, Uechi, H & Higa, F 1997, 'Clinical investigation of ciprofloxacin IV in severe and/or refractory infections in the internal medicine field', Japanese Journal of Chemotherapy, vol. 45, no. 11, pp. 933-935.

@article{0552a172ae0549fb8566d2e19f1b0b4b,

title = "Clinical investigation of ciprofloxacin IV in severe and/or refractory infections in the internal medicine field",

abstract = "The efficacy, safety and usefulness of injectable ciprofloxacin (CPFX) were investigated in a clinical study involving treatment of patients with severe and/or refractory infections in the internal medicine field. The test drug was administered by intravenous drip infusion at a dose of 300 mg (as CPFX), twice daily for 3 to 14 days. A total of 66 cases were enrolled in this study: 16 cases with chronic bronchitis, 23 with infectious bronchiectasis, 20 with secondary infection with chronic respiratory disease and 2 with empyema, but 5 cases had ineligible diseases. The clinical efficacy rate was 69.1% (38/55 cases), being 92.3% (12/13) for chronic bronchitis, 59.1% (13/22) for infectious bronchiectasis, 72.2% (13/18) for secondary infection with chronic respiratory disease. The subtotals were 71.7% (38/53) for the above chronic lower RTIs and 0/2 for empyema. The efficacy rate in poor responders to antibiotic pretreatment was 66.7% (8/12 cases). The elimination rate of causative organisms was 65.7% (23/35 strains), in terms of bacteriological efficacy. Side effects were noted in 11.3% (7/62) with 10 events. The major signs and symptoms were central nervous system disorders and gastro-intestinal symptoms, all of which were mild to moderate, and disappeared during treatment or after the completion of treatment or drug discontinuation. Abnormal laboratory findings were seen in 13.1% (8/61) with 19 events, mostly GOT, GPT and/or γ -GTP elevation. In the evaluation of overall safety, a safety rate of 77.4% (48/62 cases) was obtained, yielding a 62.1% (36/58 cases) usefulness rate. Therefore, the present study confirmed good effectiveness and safety for injectable CPFX in the treatment of severe and/or refractory chronic airway infections.",

author = "Kohei Hara and Shigeru Kohno and Kadota, {Jun Ichi} and Kazunori Tomono and Yoichi Hirakata and Shigefumi Maesaki and Masao Nakatomi and Sadahiro Asai and Kazuhiro Okuno and Naomi Itoh and Yuichi Inoue and Yuko Yamashita and Takao Koike and Katsunori Onishi and Mitsuhide Omichi and Yomei Hiraga and Akira Watanabe and Toshihiro Nukiwa and Kazuo Sato and Toshio Nakamura and Masaaki Arakawa and Kouichi Wada and Kenichi Igarashi and Yoshinori Shimazu and Yukiyoshi Kon and Hiroyuki Sega and Osamu Sekine and Yasutoshi Suzuki and Nobuki Aoki and Takao Takizawa and Toshinori Kanemura and Hisashi Takemura and Kohshu Nagao and Yoshio Hamashima and Yoshio Sakamoto and Kenji Sakata and Takeo Toyoda and Mitsuhiko Ohsumi and Yukio Noguchi and Hiroyuki Kobayashi and Shin Kawai and Hiroshi Sugiura and Susumu Sakayori and Hiroshi Oshitani and Takashi Inamatsu and Yoshishige Masuda and Yasuyuki Sano and Yasuo Arai and Chuhei Ogawa and Hirokazu Yamada and Kohya Shiba and Masaki Yoshida and Kazuhisa Okada and Tetsuo Sato and Futoshi Kotajima and Izumi Hayashi and Harumi Shishido and Atsuyuki Kurashima and Fumio Matsumoto and Iwao Sakurai and Jingoro Shimada and Shigeki Odagiri and Kaneo Suzuki and Yuji Watanuki and Kenichi Takahashi and Toshiyuki Yamamoto and Kaoru Shimokata and Hidehiko Saito and Shuzo Sakai and Keisuke Nishiwaki and Masashi Yamamoto and Masamitsu Iwata and Hiroshi Saito and Fumio Miki and Nobuhiro Narita and Keiichi Mikasa and Yoshihito Niki and Toshiharu Matsushima and Rinzo Soejima and Yoshiro Sawae and Koji Takaki and Kotaro Oizumi and Shouji Kinoshita and Yoshiyuki Mitsutake and Fumio Tanaka and Masashi Kawahara and Tsuyoshi Nagatake and Yoshiaki Utsunomiya and Moritoshi Akiyama and Masaru Nasu and Atsuro Hashimoto and Shigeru Matsukura and Hideo Mashimoto and Kazuhito Hiratani and Atsushi Saito and Masao Tateyama and Takashi Shinzato and Hiroyuki Uechi and Futoshi Higa",

year = "1997",

language = "English",

volume = "45",

pages = "933--935",

journal = "Japanese Journal of Chemotherapy",

issn = "1340-7007",

publisher = "Japan Society of Chemotherapy",

number = "11",

}

TY - JOUR

T1 - Clinical investigation of ciprofloxacin IV in severe and/or refractory infections in the internal medicine field

AU - Hara, Kohei

AU - Kohno, Shigeru

AU - Kadota, Jun Ichi

AU - Tomono, Kazunori

AU - Hirakata, Yoichi

AU - Maesaki, Shigefumi

AU - Nakatomi, Masao

AU - Asai, Sadahiro

AU - Okuno, Kazuhiro

AU - Itoh, Naomi

AU - Inoue, Yuichi

AU - Yamashita, Yuko

AU - Koike, Takao

AU - Onishi, Katsunori

AU - Omichi, Mitsuhide

AU - Hiraga, Yomei

AU - Watanabe, Akira

AU - Nukiwa, Toshihiro

AU - Sato, Kazuo

AU - Nakamura, Toshio

AU - Arakawa, Masaaki

AU - Wada, Kouichi

AU - Igarashi, Kenichi

AU - Shimazu, Yoshinori

AU - Kon, Yukiyoshi

AU - Sega, Hiroyuki

AU - Sekine, Osamu

AU - Suzuki, Yasutoshi

AU - Aoki, Nobuki

AU - Takizawa, Takao

AU - Kanemura, Toshinori

AU - Takemura, Hisashi

AU - Nagao, Kohshu

AU - Hamashima, Yoshio

AU - Sakamoto, Yoshio

AU - Sakata, Kenji

AU - Toyoda, Takeo

AU - Ohsumi, Mitsuhiko

AU - Noguchi, Yukio

AU - Kobayashi, Hiroyuki

AU - Kawai, Shin

AU - Sugiura, Hiroshi

AU - Sakayori, Susumu

AU - Oshitani, Hiroshi

AU - Inamatsu, Takashi

AU - Masuda, Yoshishige

AU - Sano, Yasuyuki

AU - Arai, Yasuo

AU - Ogawa, Chuhei

AU - Yamada, Hirokazu

AU - Shiba, Kohya

AU - Yoshida, Masaki

AU - Okada, Kazuhisa

AU - Sato, Tetsuo

AU - Kotajima, Futoshi

AU - Hayashi, Izumi

AU - Shishido, Harumi

AU - Kurashima, Atsuyuki

AU - Matsumoto, Fumio

AU - Sakurai, Iwao

AU - Shimada, Jingoro

AU - Odagiri, Shigeki

AU - Suzuki, Kaneo

AU - Watanuki, Yuji

AU - Takahashi, Kenichi

AU - Yamamoto, Toshiyuki

AU - Shimokata, Kaoru

AU - Saito, Hidehiko

AU - Sakai, Shuzo

AU - Nishiwaki, Keisuke

AU - Yamamoto, Masashi

AU - Iwata, Masamitsu

AU - Saito, Hiroshi

AU - Miki, Fumio

AU - Narita, Nobuhiro

AU - Mikasa, Keiichi

AU - Niki, Yoshihito

AU - Matsushima, Toshiharu

AU - Soejima, Rinzo

AU - Sawae, Yoshiro

AU - Takaki, Koji

AU - Oizumi, Kotaro

AU - Kinoshita, Shouji

AU - Mitsutake, Yoshiyuki

AU - Tanaka, Fumio

AU - Kawahara, Masashi

AU - Nagatake, Tsuyoshi

AU - Utsunomiya, Yoshiaki

AU - Akiyama, Moritoshi

AU - Nasu, Masaru

AU - Hashimoto, Atsuro

AU - Matsukura, Shigeru

AU - Mashimoto, Hideo

AU - Hiratani, Kazuhito

AU - Saito, Atsushi

AU - Tateyama, Masao

AU - Shinzato, Takashi

AU - Uechi, Hiroyuki

AU - Higa, Futoshi

PY - 1997

Y1 - 1997

N2 - The efficacy, safety and usefulness of injectable ciprofloxacin (CPFX) were investigated in a clinical study involving treatment of patients with severe and/or refractory infections in the internal medicine field. The test drug was administered by intravenous drip infusion at a dose of 300 mg (as CPFX), twice daily for 3 to 14 days. A total of 66 cases were enrolled in this study: 16 cases with chronic bronchitis, 23 with infectious bronchiectasis, 20 with secondary infection with chronic respiratory disease and 2 with empyema, but 5 cases had ineligible diseases. The clinical efficacy rate was 69.1% (38/55 cases), being 92.3% (12/13) for chronic bronchitis, 59.1% (13/22) for infectious bronchiectasis, 72.2% (13/18) for secondary infection with chronic respiratory disease. The subtotals were 71.7% (38/53) for the above chronic lower RTIs and 0/2 for empyema. The efficacy rate in poor responders to antibiotic pretreatment was 66.7% (8/12 cases). The elimination rate of causative organisms was 65.7% (23/35 strains), in terms of bacteriological efficacy. Side effects were noted in 11.3% (7/62) with 10 events. The major signs and symptoms were central nervous system disorders and gastro-intestinal symptoms, all of which were mild to moderate, and disappeared during treatment or after the completion of treatment or drug discontinuation. Abnormal laboratory findings were seen in 13.1% (8/61) with 19 events, mostly GOT, GPT and/or γ -GTP elevation. In the evaluation of overall safety, a safety rate of 77.4% (48/62 cases) was obtained, yielding a 62.1% (36/58 cases) usefulness rate. Therefore, the present study confirmed good effectiveness and safety for injectable CPFX in the treatment of severe and/or refractory chronic airway infections.

AB - The efficacy, safety and usefulness of injectable ciprofloxacin (CPFX) were investigated in a clinical study involving treatment of patients with severe and/or refractory infections in the internal medicine field. The test drug was administered by intravenous drip infusion at a dose of 300 mg (as CPFX), twice daily for 3 to 14 days. A total of 66 cases were enrolled in this study: 16 cases with chronic bronchitis, 23 with infectious bronchiectasis, 20 with secondary infection with chronic respiratory disease and 2 with empyema, but 5 cases had ineligible diseases. The clinical efficacy rate was 69.1% (38/55 cases), being 92.3% (12/13) for chronic bronchitis, 59.1% (13/22) for infectious bronchiectasis, 72.2% (13/18) for secondary infection with chronic respiratory disease. The subtotals were 71.7% (38/53) for the above chronic lower RTIs and 0/2 for empyema. The efficacy rate in poor responders to antibiotic pretreatment was 66.7% (8/12 cases). The elimination rate of causative organisms was 65.7% (23/35 strains), in terms of bacteriological efficacy. Side effects were noted in 11.3% (7/62) with 10 events. The major signs and symptoms were central nervous system disorders and gastro-intestinal symptoms, all of which were mild to moderate, and disappeared during treatment or after the completion of treatment or drug discontinuation. Abnormal laboratory findings were seen in 13.1% (8/61) with 19 events, mostly GOT, GPT and/or γ -GTP elevation. In the evaluation of overall safety, a safety rate of 77.4% (48/62 cases) was obtained, yielding a 62.1% (36/58 cases) usefulness rate. Therefore, the present study confirmed good effectiveness and safety for injectable CPFX in the treatment of severe and/or refractory chronic airway infections.

UR - http://www.scopus.com/inward/record.url?scp=0031392176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031392176&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031392176

SN - 1340-7007

VL - 45

SP - 933

EP - 935

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

IS - 11

ER -

Clinical investigation of ciprofloxacin IV in severe and/or refractory infections in the internal medicine field

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this